The American Academy of Allergy Asthma & Immunology has created a website for practitioners, which can be accessed here. Below is guidance offered in the letter to members.
- There is no data to support the belief that asthma is a risk factor for COVID-19. Available data suggest that the rate of asthma in patients with severe COVID-19 is the same or lower than the general population.
- Systemic steroids are not recommended for the treatment of COVID-19, but are okay for asthma exacerbation.
- It is important to continue to manage your asthma patients and asthma exacerbations according to the guidelines. Focus on asthma control to keep our patients well and out of the emergency room (ER) and urgent care, where the risk for infection with COVID-19 is much higher. This would be a good time to ensure that all of your asthma patients are up to date on medications and treatment plans.
- There is no evidence that the biologics we use in asthma have any adverse effect on COVID-19 cases, and it would be important to continue them based on the need for asthma control.
- Steroid dependent asthmatics: Remember adjustments for adrenal insufficiency and severe infection, may need to consider stress doses of hydrocortisone even for patients on high dose ICS. See this article.Food Allergies
- Additional counseling for food allergy patients regarding the inability to choose more familiar foods or query waitpersons/chefs when getting restaurant take-out was posted in a previous message.
- The white paper on COVID-19 and the allergist just published in JACI: In Practice recommends adjusting counseling about epinephrine use in the case of a reaction, emphasizing that transportation to the ER was for the allergic reaction itself and not for potential adverse reactions to epinephrine. If the patient has a mild allergic reaction, an ER trip may not be needed even if epinephrine was administered, in order to reduce the risk for COVID-19 infection.